NCT03081923View on ClinicalTrials.gov

Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

December 6, 2019

Study Completion Date

December 6, 2019

Conditions
Germ Cell Tumor
Interventions
DRUG

Durvalumab

anti-PD-L1 mono therapy

DRUG

Tremelimumab

anti-CTLA4 drug Tremelimumab mono therapy

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER